UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 9, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
001-15281
(Commission File Number)
|
|
76-0233274
(I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On May 9, 2008 Repros Therapeutics Inc., a Delaware corporation (the “Company”), announced
financial results for the first quarter ended March 31, 2008 and provided a clinical development
program overview. Additional information is included in the Company’s press release dated May 9,
2008, which is attached hereto as Exhibit 99.1.
The information in this Item 2.02 of this Current Report is being furnished pursuant to Item
2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this
Item 2.02 of this Current Report shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The
information in this Item 2.02 of this Current Report shall not be incorporated by reference into
any registration statement pursuant to the Securities Act of 1933.
Item 8.01. Other Information
Repros Therapeutics Inc. announced in a press release today results from its pilot study of
Proellex®
in the treatment of uterine fibroids.
Item 9.01. Financial Statements and Exhibits
c. Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
99.1
|
|
Press Release dated May 9, 2008 |
99.2
|
|
Press Release dated May 12, 2008 |